Similar results were obtained in DSS-induced colitis mice, as 4-methyl-esculetin administered orally at 25 mg/kg daily, improved microscopic parameters, reduced MPO activity, lowered colonic IL-6 levels, and prevented GSH depletion compared to the DSS-control group 562. This evidence concerns the gene IL6 and colitis.